[Lymphatic neoplasias in young patients]

MeSH terms

• Adolescent
• Adult
• Age Factors
• Antibodies, Bispecific / administration & dosage
• Antibodies, Bispecific / adverse effects
• Antibodies, Monoclonal, Murine-Derived / administration & dosage
• Antibodies, Monoclonal, Murine-Derived / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / adverse effects
• Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
• Child
• Child, Preschool
• Clinical Trials as Topic
• Combined Modality Therapy
• Drug Resistance, Neoplasm
• Female
• Hematopoietic Stem Cell Transplantation
• Hodgkin Disease / drug therapy*
• Hodgkin Disease / mortality
• Hodgkin Disease / pathology
• Humans
• Lymphoma, Non-Hodgkin / drug therapy*
• Lymphoma, Non-Hodgkin / mortality
• Lymphoma, Non-Hodgkin / pathology
• Male
• Neoplasm Staging
• Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
• Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
• Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
• Prognosis
• Remission Induction
• Rituximab
• Survival Rate
• Young Adult